tbuckley/cabot-search huggingface dataset:
Abstract 35: In Singletons Born at Term, Lower Gestational Age is Associated with Lower Cardiorespiratory Fitness Levels Through Adolescence to Young Adulthood: The Northern Ireland Young Hearts Project (NIYHP)
Authors: Isabel Ferreira, Pei T Gbatu, Colin Boreham
Journal: Circulation (2017)

Decreases in the mean gestational age of term deliveries have been reported over the past decade in several developed countries, linked to increases in the rates of planned births by labour induction and/or pre-labour caesarean sections. In contrast to the effects of pre-term birth, the extent to which lower gestation age within the at-term range (i.e. 37 to 42 weeks) affects individuals’ cardiorespiratory fitness (CRF) health is largely unknown, however. We therefore examined the association between gestational age, accounting for other important perinatal covariates (obtained from the NI Child Health Services’ records), and CRF (VO 2 max) as measured through adolescence to young adulthood in 842 (51.5% female) participants in the NIYHP (all singletons born at term, 98% of whom with birth weight greater than 2.5 kg). Participants’ mean levels of CRF were 45.6 ± 4.8, 43.7 ± 6.8 and 32.9 ± 9.8 ml/kg/min at the ages of 12, 15 and 22 years, respectively. With the use of GEE analyses adjusted for age, sex, socio economic status, birth weight z-scores (relative to UK’s 1990 reference), breast-feeding practices and duration, maternal age at child’s birth and delivery mode, we found that each week increase in gestational age was associated with 0.44 ml/kg/min (95% CI 0.13 to 0.75) higher levels of CRF throughout the whole longitudinal period (p=0.005). Further adjustments for participants’ height, body fatness and maturational level throughout the longitudinal period only attenuated this association slightly [to 0.38 ml/kg/min (95% CI 0.12 to 0.65), p=0.005]. There were no significant interactions between gestational age and sex or participants’ age at the time of CRF assessment, indicating that the decreases in CRF over time were similar across the different gestational ages, with those born early term displaying consistently lower levels throughout the longitudinal period. Finally, each week increase in gestation age was associated with lower risk of poor CRF through adolescence to young adulthood as defined according to current age and sex-specific health-reference values of VO 2 max: RR=0.89 (95% 0.81 to 0.97), p=0.008. These findings suggest that lower gestational age, even within the at-term range , may be a key determinant of poorer CRF as each additional week conferred benefits. This aspect may have been neglected by the over-simplistic characterisation of individuals born at-term as a homogeneous group and may have public health and clinical implications for policies around planned deliveries, given the current trends.
Development of a heroin-addiction treatment program. Effect on urban crime
Authors: R. L. DuPont
Journal: JAMA (1971)

When the First National Conference on Methadone Treatment was held in 1968, the "crime capital of the nation," Washington, DC, had only a handful of heroin addicts participating in one treatment program. This program, called DATRC, was an outpatient abstinence program funded by the Office of Economic Opportunity and operated by the Department of Public Health. A few months later, the Senate District of Columbia Committee dramatized the growing problems of crime and heroin addiction in the nation's capital. The committee concluded that both law enforcement and treatment efforts were failing.<sup>1</sup>During the hearing, a study from the District of Columbia Department of Corrections was reviewed which demonstrated that the rate of commitment of known heroin addicts to the jail had risen gradually from about 50 to 150 cases a year from 1958 through 1966. Beginning in 1967, however, there was an exponential rise to 450 cases in 1968
Comparison of antimetabolites in the treatment of breast and colon cancer
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
VT-464: A novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC).
Authors: Joel Robert Eisner, David H Abbott, Ian M Bird, Stephen W Rafferty, William R Moore, Robert J Schotzinger
Journal: Journal of Clinical Oncology (2012)

e15167 Background: CYP17 is a single protein with two distinct enzyme activities, 17 α-hydroxylase (hydroxylase) and 17,20-lyase (lyase). Reduction of extra-gonadal androgen production through CYP17 inhibition is a validated CRPC treatment paradigm. While treatment with the recently-approved CYP17 inhibitor, abiraterone acetate (AA), increases overall survival in post-docetaxel CRPC patients (de Bono et al, N Engl J Med 2011; 364:1995-2005), it is also associated with cortisol (F) suppression and increased steroid concentrations up-stream of CYP17 hydroxylase. The clinical candidate VT-464 is an oral, non-steroidal, lyase-selective CYP17 inhibitor. The study objectives were to compare VT-464 to abiraterone in regards to in vitro selectivity and to compare VT-464 to AA in regards to in vivo primate endocrine response. Methods: Human CYP17 hydroxylase and lyase IC 50 values were determined for VT-464 and abiraterone in vitro. Plasma progesterone (P), F, and testosterone (T) responses were measured 0-24 hours after single subcutaneous doses of AA (12.5 mg/kg), VT-464 (6.25 and 12.5 mg/kg), or vehicle in adult, castrate, male rhesus monkeys. Results: Human lyase and hydroxylase IC 50 values were 69nM and 670nM for VT-464 and 15nM and 2.5nM for abiraterone, respectively. AA and both dose levels of VT-464 produced a similar overall reduction in plasma T, compared to vehicle (p ≤ 0.009). AA treatment resulted in an elevated plasma P (peak increase &gt;9,000%; p ≤ 0.05), compared to both VT-464 treatments and vehicle. F was not affected by either VT-464 dose, whereas AA resulted in F suppression (p ≤ 0.005) compared to vehicle. Conclusions: VT-464 was 10-fold more selective for human CYP17 lyase vs. hydroxylase inhibition. This selectivity was associated with androgen suppression, but not increases of up-stream steroids or F suppression in male monkeys. In contrast, abiraterone was 6-fold more selective for hydroxylase vs. lyase inhibition resulting in associations with increased up-stream steroids and F suppression in AA-treated male monkeys, consistent with clinical observations in CRPC. VT-464 may thus provide a more lyase-selective alternative to AA for extra-gonadal androgen suppression in CRPC.
Cholinergic, Not Anticholinergic Agent
Journal: JAMA (1975)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genital herpes research: many aim to tame maverick virus
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diagnostic Laparoscopy
Authors: J. L. Parra, K. R. Reddy
Journal: Endoscopy (2004)

Since the early part of the 20th century, diagnostic laparoscopy has become an important tool in the armamentarium of surgeons and gastroenterologists alike. Its indications have expanded from initial attempts at tamponading internal hemorrhage to avoidance of unnecessary laparotomies with accurate staging of malignancies, treatment of a multitude of intra-abdominal pathologies, and even as a resource for evaluating blunt abdominal trauma and chronic abdominal pain. Its accuracy has been demonstrated in the evaluation of chronic liver diseases, in comparison with other diagnostic modalities. Many further technical advances have been introduced in recent years. Gastroenterology training programs should include formal diagnostic laparoscopy training as part of their curriculum.
Wound Infection in Otolaryngologic Surgery and the Inexpediency of Antibody Prophylaxis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOARDS OF HEALTH AND LEPROSY
Journal: JAMA (1990)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Recall and eye tracking study of adolescents viewing tobacco advertisements
Authors: P. M. Fischer
Journal: JAMA (1989)

The warning on tobacco advertisements was required by the federal government, presumably as a health message to educate the public about the risks associated with tobacco use. Despite its potential public health role, there have been few published studies on the effectiveness of these warnings as a health message. The present study used well-accepted market research methods to examine adolescent viewing of tobacco advertisements. Sixty-one adolescents participated in the study. Eye tracking was used to study how participants viewed five different tobacco advertisements. The average viewing time of the warning amounted to only 8% of the total advertisement viewing time. In 43.6% of cases, the warning was not viewed at all. Following the advertisement viewing, participants were asked to identify the observed warnings within a list that included other simulated warnings. Subjects did only slightly better than random guessing in this test of recognition. Using market research criteria, the federally mandated warning must be viewed as an ineffective public health message in so far as adolescents are concerned. (<i>JAMA</i>1989;261:84-89)
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
Authors: Frank van Leth, Gunar Günther, Harald Hoffmann, Christoph Lange, Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Mathilde Fréchet-Jachym, Gina Gualano, Lorenzo Guglielmetti, Gunar Günther, Harald Hoffmann, Jan Heyckendorf, Barbara Kalsdorf, Heinke Kunst, Christoph Lange, Wiel de Lange, Damien Le Dû, Vaira Leimane, Frank van Leth, Rita Macedo, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Ioana D. Olaru, Olena Oliveira, Veronika Polcová, Emanuele Pontali, Cristina Popa, Jérôme Robert, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Nicolas Veziris, Piret Viiklepp
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Incorrect Language and List in the Supplement
Authors: Frederic Billings, Nancy Brown
Journal: JAMA (2016)

Giacomo Bellani, MD, PhD; John G. Laffey, MD, MA; Tài Pham, MD; Eddy Fan, MD, PhD; Laurent Brochard, MD, HDR; Andres Esteban, MD, PhD; Luciano Gattinoni, MD, FRCP; Frank van Haren, MD, PhD; Anders Larsson, MD, PhD; Daniel F. McAuley, MD, PhD; Marco Ranieri, MD; Gordon Rubenfeld, MD, MSc; B. Taylor Thompson, MD, PhD; Hermann Wrigge, MD, PhD; Arthur S. Slutsky, MD, MASc; Antonio Pesenti, MD; for the LUNG SAFE Investigators and the ESICM Trials Group
CORRESPONDENCE
Journal: Journal of Clinical Oncology (2003)

Adjuvant Chemotherapy for Node-Positive Breast Cancer Patients: Which is the Reference Today?To the Editor: During the 2002 ASCO meeting, focus was drawn on the BCIRG 001 trial 1 comparing six cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC) to six cycles of fluorouracil, doxorubicin and cyclophosphamide (FAC) regimen in adjuvant treatment of node-positive (Nϩ) breast cancer patients.After a 33-month follow-up, this trial showed interesting results, challenging usual practices in this setting.The French Adjuvant Study Group (FASG), which had a long and wide experience in this area, would like to point out some issues of the BCIRG 001 trial.For many years, we considered six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) 100 (6 FEC 100) regimen as our standard adjuvant chemotherapy for Nϩ breast cancer patients.Our position is based on two major trials.The first trial (GFEE 01) 2 , in the metastatic setting, demonstrated that epirubicin was as effective as, and less toxic than, doxorubicin when administered at equimolar doses (50 mg/m 2 ).The second trial (FASG-05),
Síntesis de Medicamentos Orgánicos.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CACHEXIA OF MALIGNANT TUMORS.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Regulation of gene expression by interleukin-6 in fetal rat hepatocyte primary cultures: Role of epidermal growth factor and dexamethasone*1
Authors: C RONCERO
Journal: Hepatology (1995)

Fetal rat hepatocytes incubated in the absence of hormonal signals, or under proliferative (presence of epidermal growth factor [EGF]) or differentiative (presence of dexamethasone) culture conditions, showed responsiveness to interleukin-6 (IL-6). Northern blotting analysis for some typical acute phase genes such as haptoglobin and other proteins not previously identified as acute-phase reactants, such as α-fetoprotein, (β2-microglobulin, and fibronectin, showed a positive modulation by IL-6, in a dose-dependent manner. However, a well-characterized negative acute-phase reactant such as albumin was not responsive to IL-6. The well-established synergism between glucocorticoids and IL-6 on inducing transcription is absent in fetal hepatocytes. Conversely, the combination of IL-6 and EGF produced different patterns of expression, depending on the messenger RNA (mRNA) analyzed. Thus, EGF abolished the increased mRNA levels of haptoglobin caused by IL-6 but had no effect on other genes such as a-fetoprotein and fibronectin.
The physician and the civic self
Authors: D. E. Detmer
Journal: JAMA (1980)

How does a physician serve? How should he serve? Peter Dans, MD, has written a quietly provocative article on physicians and health policy that makes a number of apt observations about physicians and the "big picture" (p 1451). He presents these views in the context of a brief description of the Institute of Medicine's Robert Wood Johnson Health Policy Fellows Program (not to be confused with the Robert Wood Johnson Clinical Scholars Program)—a program that has been a success by all indications. Since its inception, competition for the fellowships has been keen. But what happened to the fellows themselves after leaving the program? What of their reentry? Have the physicians among them remained clinically active? If not, should they have? How should these physicians serve? How should any physician serve? For centuries the socialization process in medicine has overwhelmingly emphasized the values of philanthropy and "technophilia." Historically, physicians have held
Technique Has Advantages Of Hypothermia, Perfusion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal